gotop

Overview

GNT Biotech and Medicals Corporation (GNTbm) focuses on innovative drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a continuously developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

The main research and development core technologies, including the new drug combination platform for tumor microenvironment regulation, the epigenetic immunomodulation platform and the technology platform of proteolysis target protein degradation drug (HPTC, HDACs Proteolysis Targeting Chimera), are applied for the development of tumor immunotherapy. The novel and effective anti-cancer mechanisms based on the design and combinatorial strategy provided through these platforms can effectively improve the therapeutic benefits of treatment for patients with advanced cancer and in the future hope to achieve the goal of clinical cure.

On the other hand, GNTbm has cooperated with international pharmaceutical company Chipscreen Biosciences to develop the world's most promising HDACi --- Chidamide/Tucidinostat, for the treatment of peripheral T-cell lymphoma, breast cancer and other new indications.

GNTbm has devoted to develop new treatment with novel anti-cancer mechanism, better safety and better efficacy to meet the clinical unmet needs of patients with advanced and refractory cancers.
 

Business Model



 

Vision

Cancer is a great enemy of human existence, taking a lot of precious lives every year, especially advanced cancer. How to meet the treatment needs of patients with advanced and refractory cancer, so that patients have the opportunity to achieve clinical cure, is the goal of GNTbm’s efforts to pursue. GNTbm focuses on the field of epigenetic regulation research, including tumor microenvironment regulation, epigenetic immumodulation, and HDACs 1, 2, 3 proteolysis target protein degradation, is committed to solving the urgent treatment needs of patients with advanced and refractory cancer. 

GNTbm will optimize technologies and platforms through innovation and research and development. With these advanced and innovative technologies and platforms, GNTbm has focused in the development of epigenetic regulators, new combinations of tumor microenvironment regulators, epigenetic immunomodulators and HDACs 1, 2, 3 proteolysis target protein degradation drugs, in the field of tumor immunotherapy.  We envision to maximize their effectiveness by providing and reassuring more effective medical treatment for patients with advanced and refractory cancers, improving and optimizing the therapeutic benefits and quality of life of patients, and giving patients with advanced cancers a chance to achieve clinical cure.

 

Mission

GNTbm’s mission is to become a pioneer in the field of cancer epigenetics. The application to tumor immunotherapy with the development of epigenetic regulators, tumor microenvironment regulators and HDACs 1, 2, 3 proteolysis target protein degradation drugs, is dedicated to solve the issues that existing drugs can not cure the late-stage and refractory cancers. 

Based in Taiwan, but with a global focus, GNTbm is committed to epigenetics research and drug development, which will give Taiwan a place on the world stage in the field of cancer immunotherapy.